Serum albumin levels are associated with cardioembolic and cryptogenic ischemic strokes: Northern Manhattan Study
- PMID: 24549868
- PMCID: PMC3966953
- DOI: 10.1161/STROKEAHA.113.003835
Serum albumin levels are associated with cardioembolic and cryptogenic ischemic strokes: Northern Manhattan Study
Abstract
Background and purpose: Low serum albumin concentrations have been associated with increased stroke risk, but the underlying mechanisms are less well studied. We aimed to investigate the association between serum albumin levels and ischemic stroke etiologies in a large, population-based, multiethnic, prospective, cohort study.
Methods: Participants from the Northern Manhattan Study (NOMAS; n=2986; mean age, 69±10 years) free of stroke at baseline were followed for incident stroke (a median follow-up of 12 years). Cox proportional hazard models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for baseline serum albumin levels and risk of ischemic stroke and ischemic stroke subtypes after adjusting for vascular risk factors.
Results: The mean baseline serum albumin level was 4.42±0.33 g/dL. There were 271 ischemic strokes during follow-up. Participants with serum albumin levels of 2.7 to 4.2 g/dL (the lowest tertile) had increased risk of all stroke (HR, 1.76; 95% CI, 1.32-2.35), ischemic stroke (HR, 1.67; 95% CI, 1.21-2.29), cardioembolic stroke (HR, 1.92; 95% CI, 1.10-3.34), and cryptogenic stroke (HR, 2.59; 95% CI, 1.21-5.53), compared with those with levels of 4.6 to 5.5 g/dL (the top tertile; reference). Low albumin levels (2.7-4.2 g/dL) were not associated with large vessel or lacunar stroke.
Conclusions: Our study shows an association between low serum albumin levels and ischemic stroke, particularly cardioembolic and cryptogenic subtypes. These results suggest the potential shared pathophysiological relationship between low serum albumin levels, cardiac embolism, and cryptogenic infarction, which warrants further investigation.
Keywords: prospective studies; serum albumin; stroke.
Figures
References
-
- He P, Curry FE. Albumin modulation of capillary permeability: Role of endothelial cell [ca2+]i. The American journal of physiology. 1993;265:H74–82. - PubMed
-
- Jorgensen KA, Stoffersen E. On the inhibitory effect of albumin on platelet aggregation. Thrombosis research. 1980;17:13–18. - PubMed
-
- Belayev L, Zhao W, Pattany PM, Weaver RG, Huh PW, Lin B, et al. Diffusion-weighted magnetic resonance imaging confirms marked neuroprotective efficacy of albumin therapy in focal cerebral ischemia. Stroke. 1998;29:2587–2599. - PubMed
-
- Djousse L, Rothman KJ, Cupples LA, Levy D, Ellison RC. Serum albumin and risk of myocardial infarction and all-cause mortality in the framingham offspring study. Circulation. 2002;106:2919–2924. - PubMed
-
- Mukamal KJ, Tolstrup JS, Friberg J, Gronbaek M, Jensen G. Fibrinogen and albumin levels and risk of atrial fibrillation in men and women (the copenhagen city heart study). The American journal of cardiology. 2006;98:75–81. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
